The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|January 17, 2022
Dr. Jonasch shares advice for physicians treating patients with kidney cancer
Author(s)Urology Times staff
Advertisement
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, offers his advice for physicians treating patients with renal cell carcinoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5